

1 **Exploring the ATN classification system using Brain Morphology**

2 Nils Heinzinger^{1,2}, Anne Maass^{1,2}, David Berron^{1,2}, Renat Yakupov^{1,2}, Oliver Peters^{3,4},
3 Jochen Fiebach²⁹, Kersten Villringer²⁹, Lukas Preis⁴, Josef Priller^{3,5,27,28}, Eike Jacob
4 Spruth^{3,5}, Slawek Altenstein^{3,5}, Anja Schneider^{6,7}, Klaus Fliessbach^{6,7}, Jens
5 Wiltfang^{9,10,25}, Claudia Bartels¹⁰, Frank Jessen^{6,11,24}, Franziska Maier¹¹, Wenzel Glanz¹,
6 Katharina Buerger^{12,13}, Daniel Janowitz¹³, Martin Dichgans^{12,13}, Robert
7 Perneczky^{12,18,19,20}, Boris-Stephan Rauchmann¹⁸, Stefan Teipel^{14,15}, Ingo Killimann^{14,15},
8 Doreen Göerß¹⁵, Christoph Laske^{16,17}, Matthias H. Munk^{16,17}, Annika Spottke^{6,8}, Nina
9 Roy⁶, Michael T. Heneka^{6,7}, Frederic Brosseron^{6,7}, Laura Dobisch¹, Michael Ewers¹²,
10 Peter Dechent²¹, John Dylan Haynes²², Klaus Scheffler²³, Steffen Wolfsgruber^{6,7}, Luca
11 Kleineidam⁶, Matthias Schmid^{6,26}, Moritz Berger²⁶, Emrah Düzel^{1,2,*}, Gabriel Ziegler^{1,2,*}

12 * Shared last-authorship, ¹ German Center for Neurodegenerative Diseases (DZNE), Magdeburg,
13 Germany, ² Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University,
14 Magdeburg, Germany, ³ German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany, ⁴
15 Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Department of Psychiatry, Berlin,
16 Germany, ⁵ Department of Psychiatry and Psychotherapy, Charité, Berlin, Germany, ⁶ German Center for
17 Neurodegenerative Diseases (DZNE), Bonn, Germany, ⁷ University of Bonn Medical Center, Dept. of
18 Neurodegenerative Diseases and Geriatric Psychiatry/Psychiatry, Bonn, Germany, ⁸ Department of
19 Neurology, University of Bonn, Bonn, Germany, ⁹ German Center for Neurodegenerative Diseases (DZNE),
20 Göttingen, Germany, ¹⁰ Department of Psychiatry and Psychotherapy, University Medical Center Göttingen,
21 University of Göttingen, Göttingen, Germany, ¹¹ Department of Psychiatry, University of Cologne, Medical
22 Faculty, Cologne, Germany, ¹² German Center for Neurodegenerative Diseases (DZNE), Munich,
23 Germany, ¹³ Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich,
24 Germany, ¹⁴ German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany, ¹⁵ Department
25 of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany, ¹⁶ German Center for
26 Neurodegenerative Diseases (DZNE), Tübingen, Germany, ¹⁷ Section for Dementia Research, Hertie
27 Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

28 *Tübingen, Tübingen, Germany, ¹⁸ Department of Psychiatry and Psychotherapy, University Hospital, LMU*
29 *Munich, Munich, Germany, ¹⁹ Munich Cluster for Systems Neurology (SyNergy), Munich, Germany, ²⁰*
30 *Ageing Epidemiology Research Unit (AGE), School of Public Health, Imperial College London, London,*
31 *UK, ²¹ MR-Research in Neurosciences, Department of Cognitive Neurology, Georg-August-University*
32 *Göttingen, Germany, ²² Bernstein Center for Computational Neuroscience, Charité-Universitätsmedizin,*
33 *Berlin, Germany, ²³ Department for Biomedical Magnetic Resonance, University of Tübingen, Tübingen,*
34 *Germany, ²⁴ Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD),*
35 *University of Cologne, Cologne, Germany, ²⁵ Neurosciences and Signaling Group, Institute of Biomedicine*
36 *(iBiMED), Department of Medical Sciences, University of Aveiro, Aveiro, Portugal, ²⁶ Institute for Medical*
37 *Biometry, University Hospital Bonn, Bonn, Germany, ²⁷ School of Medicine, Technical University of Munich,*
38 *Department of Psychiatry and Psychotherapy, Munich, Germany, ²⁸ University of Edinburgh and UK DRI,*
39 *Edinburgh, UK, ²⁹ Center for Stroke Research Berlin, Charité-Universitätsmedizin, Berlin, Germany*

40

41 (c) Correspondence to: Nils Heinzinger; Institute for Cognitive Neurology and Dementia
42 Research; University Hospital Magdeburg, University of Magdeburg, Leipziger Str. 44,
43 39120 Magdeburg, Germany; Email: nils.heinzinger@st.ovgu.de

44

45 Alzheimer's Research & Therapy keywords: MRI, Alzheimer's disease, memory, Voxel-
46 based Morphometry, VBM, ATN, biomarker, Amyloid

47

48 Word count for paper: 6056

49 Word count for abstract: 350

50 Character count for title: 62

51 Number of references: 80

52 Number of tables: 3

53 Number of figures: 6

54 Supplementary data:

55 Number of tables: 2

56 Number of figures: 4

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71 **Abstract**

72 **Background:** The NIA-AA proposed Amyloid-Tau-Neurodegeneration (ATN) as a
73 classification system for AD biomarkers. The Amyloid Cascade Hypothesis (ACH) implies
74 a sequence across ATN groups that patients might undergo during transition from healthy
75 towards AD: A-T-N- \rightarrow A+T-N- \rightarrow A+T+N- \rightarrow A+T+N+. Here we assess the evidence for
76 monotonic brain volume decline for this particular (Amyloid-conversion first, Tau-
77 conversion second, N-conversion last) and alternative progressions using Voxel-based
78 Morphometry (VBM) in a large cross-sectional MRI cohort.

79 **Methods:** We used baseline data of the DELCODE cohort of 437 subjects (127 Controls,
80 168 SCD, 87 MCI, 55 AD patients) which underwent lumbar puncture, MRI scanning and
81 neuropsychological assessment. ATN classification was performed using CSF-
82 A β 42/A β 40 (A+/-), CSF-phospho-Tau (T+/-), and adjusted hippocampal volume or CSF-
83 total-Tau (N+/-). We compared voxel-wise model evidence for monotonic decline of gray
84 matter volume across various sequences over ATN groups using the Bayesian
85 Information Criterion (including also ROIs of Braak stages). First, face validity of the ACH
86 transition sequence A-T-N- \rightarrow A+T-N- \rightarrow A+T+N- \rightarrow A+T+N+ was compared against
87 biologically less plausible (permuted) sequences among AD-continuum ATN groups.
88 Second, we evaluated evidence for 6 monotonic brain volume progressions from A-T-N-
89 towards A+T+N+ including also non-AD-continuum ATN groups.

90 **Results:** The ACH-based progression A-T-N- \rightarrow A+T-N- \rightarrow A+T+N- \rightarrow A+T+N+ was
91 consistent with cognitive decline and clinical diagnosis. Using hippocampal volume for
92 operationalization of neurodegeneration (N), ACH was most evident in 9% of gray matter
93 predominantly in the medial temporal lobe. Many cortical regions suggested alternative
94 non-monotonic volume progressions over ACH progression groups, which is compatible

95 with an early amyloid-related tissue expansion or sampling effects e.g. due to brain-
96 reserve. Volume decline in 65% of gray matter was consistent with a progression where
97 A status converts before T or N status (i.e. ACH/ANT) when compared to alternative
98 sequences (TAN/TNA/NAT/NTA). Brain regions earlier affected by Tau tangle deposition
99 (Braak stage I-IV, MTL, limbic system) present stronger evidence for volume decline than
100 late Braak-stage ROIs (V/VI, cortical regions). Similar findings were observed when using
101 CSF-total-Tau for N instead.

102 **Conclusion:** Using the ATN classification system, early Amyloid status conversion
103 (before Tau and Neurodegeneration) is associated with brain volume loss observed
104 during AD progression. The ATN system and the ACH are compatible with monotonic
105 progression of MTL atrophy.

106 DRKS00007966, 04/05/2015, retrospectively registered

107

108

109

110

111

112

113

114

115

116

117 **Introduction**

118 Alzheimer's disease (AD) is a slowly evolving neurodegenerative condition where initial
119 brain changes can be found up to decades before the clinical onset and ultimately result
120 in prodromal cognitive decline and brain atrophy often studied with Magnetic Resonance
121 Imaging (MRI)¹⁻³.

122 AD is characterized by the accumulation of protein deposits, i.e. β -Amyloid plaques and
123 neurofibrillary tangles (NFT) consisting of hyperphosphorylated Tau which can be
124 assessed using cerebrospinal fluid (CSF) biomarkers^{4,5}. A reliable marker reflecting
125 Amyloid deposition is the A β 42/A β 40 ratio which decreases with increasing deposition⁶.
126 Accumulation of Tau tangles is mirrored by increasing CSF hyperphosphorylated Tau,
127 while CSF total Tau has been more generally associated with neuronal loss, not
128 necessarily AD specific. Those biomarkers have shown potential for predicting the clinical
129 diagnostic conversions⁷⁻⁹ and worsening of memory performance during disease
130 progression¹⁰.

131 One key concept about the disease progress and pathological timeline has been
132 introduced as the Amyloid Cascade Hypothesis (ACH)^{11-13,1}. Due to different
133 predispositions, including age¹⁴, genes¹⁵ or vascular risk factors¹⁶, β -Amyloid is
134 increasingly formed from precursor proteins which leads to its aggregation in the brain.
135 Then, β -Amyloid can induce hyperphosphorylation and malformation/misfolding of
136 intracellular Tau proteins, which aggregate in forms of NFTs¹³. Increased cellular stress
137 results in neuronal loss which typically manifests behaviourally in progressive cognitive
138 decline. Neuronal death in AD manifests in a typical MRI atrophy pattern with strongest
139 morphometrical changes situated in medial temporal lobe (MTL) and other limbic regions,
140 while the primary motor and sensory cortex are often spared^{17,18}. Although the ACH was

141 postulated about 30 years ago, the hypothesis is still under refinement and critical
142 review^{13,19,20}. Moreover, the stereotypical progression pattern of Tau/NFT spread from
143 the transentorhinal region via the limbic system to the whole cortex during AD progression
144 can be classified into six Braak stages, which have been first described in an autopsy
145 study⁵, and later tested in positron emission tomography studies^{21,22} or VBM atrophy
146 studies²³.

147 Recently, a new descriptive ATN classification for AD which emphasises pathological and
148 physiological rather than traditional clinical measures such as neuropsychological test
149 scores was proposed^{24,25}. In the ATN system, for the three binary categories Amyloid
150 burden, Tau burden and Neurodegeneration, subjects are rated as normal (physiological,
151 “-“) or abnormal (pathological, “+“). The resulting 8 ($=2^3$) groups with different biomarker
152 combinations range from A-T-N- (suggesting no pathology) to A+T+N+ (with pathology in
153 all categories). It has been suggested that all ATN biomarker combinations with A+ reflect
154 a pathological change related to the AD continuum. Several recent studies explored the
155 prognostic possibilities for clinical progression and cognitive decline using ATN²⁶⁻³⁰.
156 However, while the ATN classification does not directly imply a progression cascade or a
157 set of subsequently following stages per se, it may be used for this particular purpose.
158 For example, the sequence of a disease transition across pathology groups (1) A-T-N-
159 (2) A+T-N- (3) A+T+N- (4) A+T+N+ is more compatible with the amyloid cascade
160 hypothesis than other progression sequences based on ATN classification groups²⁵. If
161 individual participants follow this particular disease progression profile, this would imply
162 a monotonic volume loss across groups (1)→(2)→(3)→(4) in brain areas associated with
163 AD. While above progression sequence is partially supported in selected studies^{31,32},
164 those findings are limited to recordings of non-imaging between-group biomarker
165 differences. Although there is evidence for deviating sequences of progression³², studies

166 focusing on local voxel-based anatomical analysis in relation to ATN groups are still
167 missing (see eg.³³).

168 Here we study whether above progression implied by the ACH is reflected in specific
169 patterns of local GM volume decline using cross-sectional data from a large neuroimaging
170 cohort (DELCODE; DZNE Longitudinal Cognitive Impairment and Dementia Study) which
171 is well characterized by CSF biomarkers. The DELCODE cohort is specifically enriched
172 in subjects that are at risk for developing AD such as Subjective Cognitive Decline (SCD),
173 but also Mild Cognitive Impairment (MCI) and thus more likely comprises individuals in
174 early preclinical stages of AD (A+).

175 GM volume is a sensitive marker for local brain changes or pathological processes. As
176 this marker is continuous, smallest substance differences for all brain regions can be
177 measured and intermediate changes are detectable even when they would not cause an
178 ATN status conversion. We hypothesize that GM in the hippocampal-network decreases
179 following the ACH sequence and (1) test face validity of an ACH-based sequence using
180 Voxel-based Morphometry without *a-priori* regional assumptions; and (2) compare the
181 evidence for volume loss reflecting the ACH sequence in comparison to other biologically
182 possible progressions outside the AD continuum. Finally, the concordance between ACH
183 progress and Braak staging is evaluated. We expect earlier Braak stages to be stronger
184 affected by atrophy during the ACH sequence. It might occur that the volume alteration is
185 regionally modulated by e.g. reserve mechanisms. Since operationalization might be
186 crucial, we also evaluate the impact of alternative choices for dichotomization of the N
187 category using both t-Tau or hippocampal volume.

188

189 **Methods**

190 **Study Design and Participants**

191 This study uses the baseline data of the DELCODE cohort, an observational multicentre
192 study with 10 sites from the German Centre of Neurodegenerative Diseases (DZNE). Its
193 focus is the multimodal assessment of preclinical stages of dementia of Alzheimer's type
194 (DAT) including SCD, MCI, DAT, and DAT relatives³⁴. While SCD, MCI and DAT
195 participants were recruited from memory clinics, relatives of DAT patients and healthy
196 controls were recruited by advertisement and initially screened per phone for self-
197 experienced cognitive decline and memory worries. Further SCD inclusion criteria were
198 a normal cognitive performance (specified as within 1.5 SD compared to an age, sex and
199 education years adjusted control group) in all subtests of the CERAD-plus battery and a
200 MMSE score between 26 and 30 and a CDR score ≤ 0.5 .

201 Participants with MCI were below 1.5 SD in the CERAD-plus battery, but did not fulfil
202 dementia criteria of NINDCS/ADRDA³⁵. Subjects diagnosed as DAT were fulfilling
203 NINDCS/ADRDA criteria, have a CERAD-plus score of below 1.5 SD, and were within an
204 extended MMSE score range of 18-26 and have a CDR rating of ≥ 1 . DAT relatives have
205 a first-grade sibling with diagnosed DAT and do not fulfil MCI or DAT criteria.

206 Noncomplaining healthy controls (NC) neither suffered from subjective or objective
207 cognitive impairment. All participants were native German speakers, older than 60 years,
208 and gave written informed consent and had a study partner available for consultation.

209 Other neurological or psychiatric disorders than DAT were excluded. More information on
210 study design and inclusion/exclusion criteria can be found elsewhere³⁴. DELCODE is
211 retrospectively registered at the German Clinical Trials Register (DRKS00007966),
212 (04/05/2015) and was approved by ethical committees and local review boards. Of a total
213 of 1079 participants at baseline timepoint, we finally included 437 subjects with available

214 quality checked MRI imaging and CSF biomarkers (see below). Based on a clinical
215 classification approach, this includes 127 NC (including DAT relatives), 168 SCD, 87 MCI
216 and 55 DAT patients. A summary of demographic information of the analysed sample is
217 provided in results table 1.

218 **Neuropsychological testing**

219 In DELCODE, subjects underwent a large battery of neuropsychological tests. Due to our
220 focus on global cognition and memory aspects in healthy and (pre-) clinical DAT patients,
221 we use the Mini Mental State Examination (MMSE, ³⁶) and a reliable memory composite
222 factor score (further denoted as memory performance). This score was created by
223 Confirmatory Factor Analysis and enables detecting subtle cognitive deviations in SCD
224 when compared to NC subjects³⁷.

225 **Biomarker and MRI data acquisition**

226 Lumbar puncture was carried out by trained study assistants in 49% of DELCODE
227 participants. CSF samples were centrifuged, aliquoted and stored at -80°C for retests.
228 Biomarkers known to be related to AD pathology (CSF A β 42, Total Tau,
229 hyperphosphorylated Tau) were determined by commercially available kits (V-PLEX A β
230 Peptide Panel 1 (6E10) Kit (K15200E), V-PLEX Human Total Tau Kit (K151LAE) (both
231 Mesoscale Diagnostics LLC, Rockville, USA), Innotest Phospho-Tau(181P) (81581;
232 Fujirebio Germany GmbH, Hannover, Germany)).

233 MRI scans were acquired in 9 out of 10 involved DZNE sites (3T Siemens scanners: 3
234 TIM Trio systems, 4 Verio systems, 1 Skyra and 1 Prisma system). Our main analyses
235 were based on whole brain T1-weighted MPRAGE (3D GRAPPA PAT 2, 1 mm³ isotropic,
236 256 X 256 px, 192 slices, sagittal, ~5 min, TR 2500 ms, TE 4.33 ms, TI 110 ms, FA 7°).
237 Further ROI and covariate processing was based on additionally available FLAIR and T2-

238 weighted protocols (for details see³⁴). Additional details on standard operation
239 procedures, quality assurance and assessment (QA), performed by the DZNE imaging
240 network (iNET, Magdeburg), can be found elsewhere³⁴.

241 **Image processing and computational brain morphometry**

242 The MPRAGE images were processed using SPM (SPM12 v7771, Statistical Parametric
243 Mapping software; Wellcome Trust Centre for Human Neuroimaging, London, UK, ³⁸) and
244 CAT-Toolbox (CAT12.6 r1450, Structural Brain Mapping group, Jena University Hospital,
245 Jena, Germany, ³⁹) under MATLAB (r2019b, The MathWorks, Inc., Natick,
246 Massachusetts, USA). As first step, a correction for field inhomogeneities was applied.
247 Then the images were segmented into GM, WM and CSF maps using CAT which includes
248 a partial volume estimation correction on AMAP approach⁴⁰. The received tissue maps
249 with a 1 mm isometric voxel size are warped to a study-specific template in MNI space
250 using Geodesic Shooting approach⁴¹. The GM tissue maps were modulated by the
251 jacobian determinant to enable voxel-based comparisons of local gray matter volume
252 across subjects. A Gaussian blurring kernel was applied with 6 mm full width half
253 maximum (FWHM). The resulting tissue maps were quality tested using CAT's sample
254 homogeneity check and 15 subjects were excluded due to preprocessing artifacts.

255 For complementary ROI analysis we used Freesurfer's (v6.0, ⁴²) volume reconstruction
256 (cortical stream⁴³, subcortical stream⁴⁴) to extract region of interest volumes. This was
257 carried out by the default pipeline initiated by a 'recon-all -all' command which contains
258 all preprocessing steps needed, including for example intensity normalization, surface
259 registration to Talairach space, skull stripping, subcortical segmentation and calculation
260 of affiliated region statistics, WM segmentation, tessellation and inflation of pial
261 parcellated WM surfaces and cortical parcellation with calculation of cortical region

262 statistics. Four ROIs (amygdala, hippocampus, entorhinal cortex, precuneus), well known
263 to be affected early by AD pathology, were assessed^{45-47,17,48}. Furthermore, anatomical
264 masks representing Braak stages were created following⁴⁹ and warped to MNI space.
265 Thus, the following cortical regions were included as aggregated volumes: stage I/II:
266 entorhinal cortex and hippocampus, stage III/IV: limbic, insular and temporal regions,
267 V/VI: remaining cortical regions including primary sensory/motor areas or precuneus.

268 In order to enable a reliable operationalization of the N category of ATN system we used
269 the specifically developed hippocampal segmentation in Freesurfer that is based on a
270 high-resolution T2-weighted scan of the medial temporal lobe⁵⁰. Note, that the obtained
271 hippocampal volumes were only used for the ATN classification of each participant, while
272 all presented voxel-based and ROI volumes were based on conventional CAT and
273 Freesurfer segmentations (as dependent variable). A strong co-occurrence of AD and
274 white matter hyperintensities (WMH) as sign of vascular damage has been reported^{16,51-}
275 ⁵⁴. To account for WMH during our analyses, the total lesion volume was extracted using
276 Lesion segmentation toolbox (v3.0.0, LPA and an 0.5 binary threshold, ^{55,56}).

277 **ATN classification and group comparison**

278 Each participant was classified as normal (-) or abnormal (+) in the Amyloid (A) and Tau
279 (T) category depending on their biomarker levels of A β 42_{over40} and phospho-Tau181
280 respectively. Cut-offs were estimated by a ROC analysis and Youden's index (A = 0.09,
281 T = 57 pg/ml; ³⁴). In this study we explored effects of two different choices for the
282 neurodegeneration (N) category. We focused on (1) adjusted hippocampal volume
283 (denoted as aHV; cut-off = 2821.1 μ l) and (2) CSF Total Tau (cut-off = 470 pg/ml). aHV
284 was derived from the Freesurfer segmentation (see above) and corrected for age, sex,
285 education, total intracranial volume (TICV) and WMH using a linear regression model.

286 Dichotomization of participants' aHV into N- and N+ was performed using Gaussian
287 mixture modelling similar to established cut-off estimation for CSF biomarkers used for
288 the A and T category⁵⁷.

289 To assess group differences in age and education, one-way ANOVAs with ATN status as
290 between-subject variable were used. Group differences in cognition (MMSE and memory
291 performance) were tested in ANCOVAs with ATN status as between group variable and
292 age, sex and education as covariates. In all cases, post-hoc analysis was performed by
293 two sample t-tests using a Bonferroni correction to account for multiple comparisons.
294 Notably, analyses were restricted to the four groups of the ACH-based progression (1) A-
295 T-N- (2) A+T-N- (3) A+T+N- (4) A+T+N+ since we focused on implications for common
296 AD-related trajectories. The distribution of ATN status per clinical diagnosis was tested
297 by 2-sided Fisher's exact test for distribution differences between cognitively unimpaired
298 (NC, SCD) and cognitively impaired (MCI, DAT) subjects. Significance level is set to $p <$
299 $.05$ (*) or $p < .001$ (**) respectively.

300 **Testing the evidence for a monotonic decrease of brain volume over ATN** 301 **progression groups**

302 We aimed to test the evidence of local brain GM volume loss as a process of AD
303 progression. As predicted by the ACH, the volume would decline over the following
304 groups (1) A-T-N- (2) A+T-N- (3) A+T+N-; to (4) A+T+N+. Thus, we hypothesized later
305 ATN stages to be associated with significantly reduced GM in AD-related areas. We
306 estimated a voxel-wise general linear model describing the local GM volume y for the 4
307 given groups as

$$308 \quad y = X\beta + \epsilon$$

309 with design matrix X , coefficients β and residuals ϵ . The design matrix was chosen to
310 define β_1 as group mean of the first group, and for $g=2,3,4$ coefficient β_g as group
311 difference of group g and $g-1$. The model was fitted under linear constraints that $\beta_g \leq 0$
312 for $g=2,3,4$ and therefore implementing a monotonic decline of volume across groups 1
313 to 4 (using MATLAB R2019b's function for constrained optimization lsqin). For instance
314 if a voxel has a true monotonic decline of volume y over groups 1,2,3,4 the model
315 evidence is expected to be higher than for an alternative model with reversed group order
316 e.g. 4,3,2,1. We further compared different hypothesized and alternative sequences of
317 volume decline progressions using the Bayesian Information Criterion⁵⁸ (BIC) which
318 compares the likelihood how well the data is described using a monotonic function while
319 accounting for model complexity (Figure 1).

320

321

322

323

324

325

326


327

328

329

330

331 **Figure 1: Monotonic and non-monotonic volume decline using ATN.**



332

333 *A: An illustration of monotonic GM volume decline as hypothesised when following the ACH hypothesis*
334 *using ATN groups. B: A permuted order of the upper case that clearly not shows a monotonic volume*
335 *decline. A temporarily volume increase causes large residuals that cannot be explained by a monotonic*
336 *model. Therefore, the pathway in A would be preferred over B ('higher evidence for monotonic decline in*
337 *A').*

338 First, face validity of the ACH hypothesis was tested by comparing the evidence of the
339 above ACH-based sequence (1) → (2) → (3) → (4) against 23 (=4*3*2*1-1) alternative
340 monotonic progressions generated by permutation which are *a-priori* less plausible if ACH
341 is true. Note that this analysis was restricted to 4 primarily AD-related of all 8 possible
342 ATN classification groups, where it is assumed that Amyloid conversion happens before
343 status conversion of Tau and Neurodegeneration. In a second analysis, the evidence of

344 the ACH-related volume trajectory was compared against 5 biologically plausible
345 alternative sequences including also ATN groups which are considered outside the AD-
346 continuum, in particular ANT (i.e. Amyloid-conversion first, N-conversion second, Tau-
347 conversion last; therefore 'ANT'), TAN, TNA, NAT, and NTA. These 6 sequences
348 represent all conceivable possibilities to convert in three steps from A-T-N- (no pathology)
349 to A+T+N+ (full pathology).

350 In this study, all tests were performed both on (A) whole brain voxel-based modulated
351 GM volume images, and (B) a-priori hypothesized ROIs. Voxel-based tests were
352 restricted to GM using an absolute threshold of .05. In addition, the percentage of voxels
353 with the highest evidence for the ACH trajectory inside every ROI mask is provided.

354 All statistical analyses were performed in MATLAB. Voxel-wise test results are presented
355 as maps with the highest evidence for one particular model and log p maps for inference
356 on statistical parameters such as successive volume decline over groups (using FDR
357 correction for multiple comparisons, $p < 0.05$). Finally, the percentage of GM voxels with
358 the highest evidence for a certain progression sequence is provided. All analyses were
359 accounting for covariates age, sex, education, TICV and WHM. All main results are
360 reported for N operationalized by aHV and selected results using CSF Total Tau can be
361 found in the supplementary material.

362

363 **Results**

364 **Sample demographics and ATN group comparisons**

365 Key characteristics of the analysed sample are summarized in Table 1, selected
366 comparisons (Bonferroni) can be found in Figure 2. As expected we found that age

367 differed across ATN groups ($F(7,429) = 6.65, p < .001$). ATN groups showed also
 368 differences in years of education ($F(7,429) = 2.63, p < .05$). With respect to cognition, we
 369 found a significant effect of ATN group ($F(7,426) = 13.46, p < .001$), age ($F(1,426) =$
 370 $14.78, p < .001$) and education ($F(1,426) = 19.58, p < .001$) on MMSE scoring, but no
 371 effect of sex ($F(1,426) = 0.93, p = .33$). Similar results were obtained for the memory
 372 performance, where ATN status ($F(7,426) = 28.10, p < .001$), age ($F(1,426) = 44.54, p <$
 373 $.001$), education ($F(1,426) = 39.78, p < .001$) and sex ($F(1,426) = 3.87, p < .05$) were
 374 significant.

375 Table 1: Sample and ATN group overview.


	A-T-N-	A-T-N+	A-T+N-	A-T+N+	A+T-N-	A+T-N+	A+T+N-	A+T+N+
Group size	143	41	29	14	45	23	61	81
age (years) mean (SD)	69.64 (5.50)	68.10 (5.85)	70.20 (4.56)	70.86 (5.90)	69.97 (5.12)	70.91 (7.10)	73.20 (5.30)	73.46 (5.84)
sex (% female)	48.25%	48.78%	72.41%	28.57%	42.22%	39.13%	47.54%	55.56%
education years mean (SD)	14.65 (2.92)	14.71 (2.87)	13.79 (2.02)	16.57 (2.53)	14.07 (2.53)	14.43 (3.19)	13.67 (3.33)	13.75 (2.98)
MMSE mean (SD)	29.15 (1.19)	28.54 (1.98)	29.14 (1.27)	29.14 (1.61)	29.24 (0.77)	27.52 (3.29)	27.52 (3.06)	26.12 (3.23)
Memory performanc e mean (SD)	0.39 (0.51)	0.13 (0.84)	0.42 (0.67)	0.01 (0.99)	0.35 (0.64)	-0.52 (1.05)	-0.44 (1.09)	-1.18 (1.00)
CSF A β 42/40 mean (SD)	0.110 (0.011)	0.108 (0.011)	0.112 (0.013)	0.118 (0.014)	0.074 (0.012)	0.064 (0.015)	0.053 (0.011)	0.050 (0.013)
CSF phospho- Tau (pg/ml) mean (SD)	41.02 (8.81)	39.85 (11.84)	68.02 (10.88)	74.68 (19.41)	41.88 (9.99)	44.49 (9.40)	93.26 (50.38)	95.06 (31.09)
CSF Total Tau (pg/ml) mean (SD)	288.18 (89.16)	291.24 (131.09)	465.98 (115.59)	544.38 (167.71)	321.41 (104.50)	312.96 (94.48)	677.41 (335.83)	778.43 (287.03)
aHV (ml) mean (SD)	3.14 (0.21)	2.64 (0.15)	3.18 (0.24)	2.63 (0.11)	3.12 (0.21)	2.60 (0.21)	3.12 (0.23)	2.56 (0.22)

WMH (ml)	3.29	3.27	1.42	2.09	3.19	4.66	6.99	6.34
mean (SD)	(5.31)	(6.07)	(1.70)	(2.83)	(3.61)	(6.05)	(11.61)	(7.96)

376 Overview on test sample and ATN group statistics. aHV: adjusted hippocampal volume; WMH: white matter
 377 hyperintensities.

378 As shown in Figure 2, the age increased while global cognition (MMSE) and memory
 379 performance decreased following a hypothesized disease progression using the ACH
 380 sequence (A-T-N- → A+T-N- → A+T+N- → A+T+N+). No systematic pattern was found
 381 for years of education. These effects could be reproduced using CSF Total Tau for N
 382 (Supplemental File 1).

383 Figure 2: Comparison between selected ATN groups.




384
 385 *Boxplots of age, sex, cognition for selected ATN groups. *: p < .05 after Bonferroni correction, **: p < .001*
 386 *after Bonferroni correction.*

387 Association of ATN status and clinical diagnosis

388 We observed an association of the ATN status and clinical diagnosis groups comparing
 389 cognitively unimpaired (NC, SCD) and cognitively impaired (MCI, DAT) participants for A-
 390 T-N- (p < .001), A-T+N- (p < .05), A+T-N- (p < .05), A+T+N- (p < .05) and A+T+N+ (p <

391 .001). No non-random association was found for A-T-N+ ($p = .49$), A-T+N+ ($p = .40$) and
 392 A+T-N+ ($p = .26$). Compared to A-T-N-, the highest relative risk for DAT was found in
 393 A+T+N+ (30.90 times higher) and A+T-N+ (15.54 times). The lowest risk for DAT relative
 394 to A-T-N- was in A-T+N- (2.47 times higher), while no DAT cases were recorded in A-
 395 T+N+ or A+T-N-. Results suggested that more impaired clinical groups, especially DAT,
 396 were found more often among the Alzheimer's continuum ATN groups (i.e. in A+), while
 397 cognitively unimpaired status was rather associated to no brain pathology (i.e. A-T-N-).
 398 For percentual distribution see Figure 3. A similar pattern was observed for N measured
 399 by CSF Total Tau (Supplemental File 2).

400 Figure 3: Distribution of ATN status and clinical diagnosis.




401
 402 *Left: percentual distribution of selected ATN groups per clinical diagnosis; right: percentual distribution of*
 403 *clinical diagnosis per ATN groups.*

404 **Assessing face validity of the ACH hypothesis using local brain volume**

405 As a next goal, we identified brain regions where volume progression across ATN groups
 406 is compatible with the ACH hypothesis. More specifically, if the ACH is true it might be
 407 expected to observe a monotonic decline of volume over groups A-T-N- → A+T-N- →

408 A+T+N- → A+T+N+ in the hippocampal network²⁵. The regions showing significant GM
409 volume decline over this ACH sequence (of ATN biomarker conversions) are illustrated
410 in Figure 4A (log p map, $p < .05$ FDR-corrected, N based on hippocampal volume,
411 accounting for covariates age, sex, education, TICV and WMH). Strongest effects are
412 found in the MTL region (peak: left post. hipp. $x = -28, y = -22, z = -19, \log p = 86.70$).
413 Further regions with significant GM volume loss following the ACH sequence are the
414 orbital and basal forebrain, large parts of the temporal lobe, the insular cortex, the basal
415 ganglia, the cingulate gyrus, the precuneus, (medial) premotor regions and the parietal
416 and occipital lobes. When using CSF total Tau instead of hippocampal volume for
417 operationalization of the 'N' category, we observed consistent but slightly less widespread
418 shrinkage of local GM (peak: left ant. hipp. peak $x = -26, y = -10, z = -17, \log p = 21.41$,
419 Figure 4B).

420 Figure 4: Volume decline following the ACH sequence.



421
422 *Regions showing significant GM volume loss along the ACH sequence. Unmasked log p map with $p < .05$,*
423 *FDR-corrected. A: Neurodegeneration (N) defined by aHV; B: Neurodegeneration (N) defined by CSF total*
424 *Tau.*

425 It is important to note that testing for ‘any’ local volume decline over groups that align with
426 the ACH-related progression might still reveal brain areas where alternative disease
427 progressions are even more likely. Therefore, in an explorative analysis we compared
428 voxel-wise evidence of the hypothesized ACH progression (or model) against 23
429 biologically less plausible (permuted) conversion sequences among the ATN
430 classification groups associated with the AD continuum e.g. the above stated group
431 progression but in reversed order. First, we applied a voxel-based test of monotonic GM
432 volume decline using the Bayesian Information Criterion. Figure 5a illustrates the
433 resulting regions with highest evidence for three selected progressions. Since only one
434 sequence of diagnostic conversions can have the highest evidence in a given brain region
435 (when compared to other progressions), these maps revealed non-overlapping areas of
436 the brain. For 8.99% of all explored GM brain regions, ACH was indeed found to be the
437 most evident progression sequence showing monotonic volume decline (Figure 5b). This
438 especially involved the anterior MTL, hippocampus, parahippocampal gyrus and fusiform
439 gyrus while the general pattern of regions most compatible with ACH is similar to the
440 above presented findings.

441

442

443


444

445

446

447

448 Figure 5: Face validity of ACH using VBM.



449

450 *Voxel-based evidence for monotonic volume decline over 24 sequences gained by permutation of the ACH*
 451 *sequence (ACH, A-T-N- \rightarrow A+T-N- \rightarrow A+T+N- \rightarrow A+T+N+); AP 1: A+T-N- \rightarrow A+T+N- \rightarrow A-T-N- \rightarrow A+T+N+; AP 2:*
 452 *A+T-N- \rightarrow A-T-N- \rightarrow A+T+N- \rightarrow A+T+N+; A: voxels where sequence shows highest evidence; B: percentage*
 453 *of gray matter voxels where sequence has highest evidence.*

454 However, this analysis also suggested that the ACH sequence was not the most evident
 455 progression (among 24 tested) in frontal lobe, insular cortex, precentral and postcentral
 456 gyri or the cerebellum. Our analysis revealed several brain regions in which alternative
 457 sequences over ATN groups were better reflective of monotonic volumetric decline. More
 458 specifically, alternative progressions AP 1 (A+T-N- \rightarrow A+T+N- \rightarrow A-T-N- \rightarrow A+T+N+) and AP
 459 2 (A+T-N- \rightarrow A-T-N- \rightarrow A+T+N- \rightarrow A+T+N+) showed highest evidence in 16.28% and
 460 14.05% of the GM respectively (Figure 5). Interestingly, both assume a transient volume
 461 increase when transitioning to Amyloid-positivity (i.e. GM volume of A+T-N- > A-T-N-)
 462 followed by the lowest GM volume in A+T+N+. AP 1 was the conversion sequence having
 463 highest evidence in cortical regions (especially frontal lobe, orbital frontal, premotor

464 regions, insular cortex). AP 2 showed highest evidence in parts of the posterior MTL, the
 465 middle and posterior cingulate gyrus, and cortical clusters (the precuneus, temporal,
 466 parietooccipital lobe).

467 Table 2 shows the results for a similar but complementary ROI-level analysis of
 468 monotonic GM decline in amygdala, hippocampus, entorhinal cortex and precuneus
 469 defined using an MRI atlas. The ACH-based progression was found to be the best fitting
 470 sequence to describe monotonic GM volume loss in amygdala and entorhinal cortex. For
 471 all ROIs, the ACH progression was found to be among top 5 most likely sequences (out
 472 of 24). Surprisingly, AP 1 showed highest evidence for hippocampal ROI volume loss,
 473 while the precuneus volume was best described by AP 2. One potential disadvantage of
 474 the definition of the ‘N’ category is the dependence on atlas-based ROIs, e.g. for the
 475 hippocampus. When using CSF Total Tau for definition of the ‘N’ category, the ACH
 476 sequence was also found to optimally describe monotonic GM loss especially in the MTL.
 477 On ROI level the ACH sequence was always the most or second most evident pathway
 478 (out of 24; Supplemental File 3&4).

479 Table 2: Face validity of ACH in selected ROIs.

Region	Sequence with highest evidence	T	P	ACH on rank nr. (of 24)	ACH VX%
AMG	ACH	-13.69	2.53e-34	1	80.99
Hippocampus	AP 1	-14.88	6.76e-39	5	26.27
Entorhinal Cortex	ACH	-7.30	1.13e-12	1	48.46
Precuneus	AP 2	-3.90	5.76e-05	4	13.78
Braak I/II	ACH	-16.11	1.15e-43	1	25.13
Braak III/IV	Other1	-6.97	8.59e-12	5	17.97
Braak V/VI	Other1	5.06	3.54e-07	5	7.31

480 *ROI based testing for monotonic volume decline over 24 sequences gained by permutation of the ACH*
 481 *sequence. Braak stage volumes are aggregated Freesurfer ROI volumes. ACH: A-T-N-→A+T-N-→A+T+N-*
 482 *→A+T+N+; AP 1: A+T-N-→A+T+N-→A-T-N-→A+T+N+; AP 2: A+T-N-→A-T-N-→A+T+N-→A+T+N+;*

483 *Other1: A+T+N- → A+T-N- → A-T-N- → A+T+N+. ACH VX%: Percentage of voxels with highest evidence*
484 *for ACH sequence inside the ROI mask.*


485 **Comparing progression sequences towards AD pathology including non-AD** 486 **continuum groups**

487 All above comparisons were focused on only four ATN groups from the AD continuum
488 (A-T-N-, A+T-N-, A+T+N-, A+T+N+). However, these AD continuum-related groups do not
489 enable direct comparisons of ACH-implied conversion sequences against an alternative
490 timing of events such as Tau positivity preceding Amyloid positivity (e.g. A-T+N+
491 converting to A+T+N+). We therefore compared the ACH-based sequence to five other
492 biologically possible conversion schemes from A-T-N- towards A+T+N+ (denoted as
493 ANT, TAN, TNA, NAT, NTA). For this comparison the conversion sequences are denoted
494 in the order of each biomarker becoming positive, e.g., TAN stands for: Tau category
495 becomes positive first, Amyloid second, Neurodegeneration last (A-T-N- → A-T+N- →
496 A+T+N- → A+T+N+). Again, Bayesian Information Criterion (BIC) was used to identify
497 conversion sequences with highest evidence for monotonic volume decline both on a
498 voxel as well as ROI-level.

499 Brain regions with highest evidence for above progressions are characterized in Figure
500 6. According to our analysis A-first sequences (ACH/ATN, ANT), T-first sequences (TAN,
501 TNA) and N-first sequences (NAT, NTA) showed the highest evidence for monotonic
502 volume decline in 64%, 35% and 0.01% of GM respectively. Local GM regions with
503 highest likelihood for ACH were especially found in the MTL (with an exception of the right
504 anterior hippocampus and parahippocampal gyrus), but also in the basal ganglia (caudate
505 ncl., putamen, thalamus) and precuneus. More supporting clusters for ACH/ATN were
506 observed in all cortical lobes making it clearly the most likely sequence in large parts of
507 GM in this comparison. The ANT progression showed highest evidence in complementary

508 regions of the MTL not covered by ACH/ATN (see above) with additional regions in the
 509 basal ganglia (incl. accumbens), medial frontal lobe, the insular cortex and premotor
 510 regions. T-first sequences were most likely only in the cerebellum and some cortical
 511 regions including the medial occipital lobe. All of these four sequences showed evidence
 512 for different parts of the cingulate gyrus. N-first sequences were only seen in very minor
 513 portions of the GM.

514 Figure 6: Comparing progression sequences towards AD pathology using VBM.



515
 516 *Regions with highest evidence for monotonic volume decline assuming 6 potential disease progressions*
 517 *from A-T-N- towards A+T+N+ (ACH, ANT, TAN, TNA, NAT, NTA). Sequences are denoted in the order of*
 518 *biomarker positivity along the pathway (e.g. ANT = Amyloid-positivity first, Neurodegeneration second, Tau*
 519 *last). A: voxels where sequence shows highest evidence; Notably, regions of highest evidence for each*
 520 *progression are disjunct. B: percentage of gray matter voxels where sequence has highest evidence. N-*
 521 *first sequences (NAT, NTA) are not shown as only few voxels are supported.*

522 In the complementary ROI analysis, conversion sequences with monotonic volume
 523 decline were compared for same ROIs as above. The most evident sequences for volume

524 loss per ROI and matching effect size are presented in Table 3. Interestingly, ACH/ATN
 525 was the most evident progression for amygdala, entorhinal cortex and precuneus. In
 526 hippocampus however, the ANT progression was found to show the highest evidence for
 527 the data. Our analysis revealed no indications for the superiority of T-first or N-first over
 528 A-first sequences in these ROIs. Notably, above findings were mainly reproduced using
 529 CSF Total Tau as neurodegeneration marker. Here, ACH was also the most prominent
 530 sequence: On voxel-level, more than 41% of GM showed highest evidence for the ACH
 531 sequence (Supplemental File 5). On ROI-level, ACH was the most evident sequence with
 532 exception of amygdala and entorhinal cortex, where TAN was more likely which is in
 533 contrast to the results of aHV-based Neurodegeneration (Supplemental File 6).

534 Table 3: Comparing progression sequences towards AD pathology including non-AD
 535 continuum groups in selected ROIs.

Region	Best sequence	T	P	ACH on rank nr. (of 6)	ACH VX%
AMG	ACH	-12.93	8.22e-33	1	89.62
Hippocampus	ANT	-18.07	5.74e-55	2	58.18
Entorhinal Cortex	ACH	-7.25	9.78e-13	1	89.05
Precuneus	ACH	-3.93	4.86e-05	1	30.92
Braak I/II	ACH	-16.20	1.07e-46	1	57.95
Braak III/IV	ANT	-7.67	5.64e-14	2	46.02
Braak V/VI	ANT	-4.21	1.53e-05	2	28.60

536 *ROI based testing for monotonic volume decline over 6 possible sequences from A-T-N- towards A+T+N+*
 537 *(ACH, ANT, TAN, TNA, NAT, NTA). Braak stage volumes are aggregated Freesurfer volumes of regions*
 538 *that mirror Braak stages. ACH VX%: Percentage of voxels with highest evidence for ACH sequence inside*
 539 *the ROI mask.*

540 **Concordance of Braak stage trajectory and the ACH trajectory**

541 In addition to above reported ROIs, the two voxel-based analyses of compatibility of the
 542 ACH sequence with monotonic GM volume decline were aggregated for larger Braak

543 stage composite regions (Table 2 & 3). Here, stage I/II encompasses the hippocampus
544 and entorhinal cortex, stage III/IV the limbic regions and stage V/VI the remaining cortical
545 regions like precuneus or primary sensory/motor regions. We asked, how much of GM at
546 some stage showed highest evidence for ACH. On voxel-level, the percentage of voxels
547 with highest evidence for the ACH sequence decreased from 25.1% in stage I/II to 7.3%
548 in stage V/VI for the first comparison (face validity of ACH). For the second comparison
549 (including non-AD continuum groups) there was also a noticeable decrease of ACH
550 compatible GM voxels from 58.0% in stage I/II to 28.6% in stage V/VI (see Table 2 & 3).

551 Thus, on ROI-level, ACH-related ATN sequence across groups was the most evident
552 conversion sequence which is compatible with a monotonic volume decline in Braak stage
553 I/II. For ROIs reflecting stages III/IV and V/VI, ACH was under the most evident 5 (of 24)
554 respectively 2 (of 6) sequences and thus not the most likely explanation for decline
555 anymore. Test statistics and p-values were decreasing with higher Braak stages (stage
556 I/II & III/IV: $p < .001$; V/VI: $p < .05$) which supports that ACH compatibility reduces with
557 Braak stage. Using CSF Total Tau instead of hippocampal volume, a similar trend was
558 observed while more voxels supported ACH in stage I/II (stage I/II & III/IV: $p < .001$; V/VI:
559 $p > .05$), Supplemental File 3&6).

560

561 **Discussion**

562 Since the ATN classification was postulated in 2016²⁴, several studies compared ATN
563 groups to a traditional clinical dementia classification^{26,27,59,30,29,60,61}. However, a
564 discussion of ATN in context of biological or structural brain changes during AD including
565 local (e.g. voxel-based) brain morphology and the Amyloid Cascade Hypothesis (ACH)

566 can be found to a much lesser extent in previous research³¹⁻³³. This study aimed to focus
567 on these neglected aspects of interest.

568 Our comparison between ATN status and clinical diagnosis suggested advanced clinical
569 diagnostic status with increasing pathology levels following the ACH group conversion
570 sequence. This is consistent with earlier work^{27,59,30} where a similar pattern has been
571 observed. The A+T+N+ group has previously been reported to show the highest
572 conversion rate to DAT and an increased risk for cognitive decline^{26,27,29,60,30,61}. In line
573 with these findings our results suggested substantial memory performance reductions in
574 later ATN stages.

575 Using MRI and voxel-based morphometry (VBM) we first tested the face validity of a
576 monotonic GM volume decline over the 4 ATN stages (1) A-T-N- (2) A+T-N- (3) A+T+N-
577 (4) A+T+N+ as implied by the ACH and previous work suggesting GM volume loss during
578 ACH progression in clinical DAT. In contrast to previous with strong prior assumptions
579 about ROIs, our emphasize here was on reporting also complementary voxel-based
580 results. More specifically, in line with previous findings brain regions following monotonic
581 volume decline over ATN stages (1)-(4) involved the hippocampus^{62,17,46,45,63-68},
582 amygdala^{62,17,46,45,65,67,68}, temporal gyri^{17,46,64,66,67}, thalamus^{62,17,65,63}, precuneus^{62,17,64,66}
583 and cingulate gyrus^{62,17,63,64,66,69}. Consistent with some previous work^{69,63,66} a decline in
584 parts of the cingulate gyrus and insula were observed in our study. Regions that are
585 expected to be affected in very late AD such as frontal^{17,66} and occipital^{64,45,63,66} lobes or
586 less affected such as those around central sulcus^{46,64,66} showed only minor effects in
587 terms of a monotonic decline over ATN stages (1)-(4).

588 Notably the ACH is still part of an ongoing discussion as anti-amyloid treatments showed
589 only limited success^{70,71}. Furthermore, the causal link between Amyloid, Tau and resulting

590 neurodegeneration and dementia is a challenging research topic^{19,20} which might be
591 mediated by alterations in neuropil⁷¹, synapses⁷² or functional connectivity⁷³. Our study
592 revealed strong evidence for an ACH-related monotonic atrophy pattern both on voxel-
593 level but also on ROI-level especially focussed on typical AD-related regions such as the
594 MTL. However, we also observed many gray matter areas where a monotonic volume
595 trajectory along the ACH-implied group progression sequence did show the highest
596 evidence. We identified alternative progressions (denoted AP 1 and AP 2) indicating that
597 there are several cortical regions where the GM volume was found to be higher in the
598 A+T-N- group than in A-T-N-. These were mainly found in cortical regions which are often
599 less strongly affected by AD^{66,17}. One might speculate that either Amyloid deposition
600 related tissue expansion^{74,75} and/or sampling effects due to individual differences of brain
601 reserve⁷⁶ might alter brain volume patterns across ATN groups and the progression along
602 the ACH trajectory. A biphasic model of neurodegeneration has been previously
603 suggested by Fortea et al.⁷⁴ hypothesizing that cortical thickening might occur when A β
604 becomes abnormal, which presumably reflects inflammation-related swelling, followed by
605 thinning once tau pathology emerges. The authors found Amyloid-related thickness
606 increases in middle temporal, inferior and superior parietal, occipital regions and
607 precuneus which is similar to our findings. Another recent publication also observed
608 Amyloid-related regional volume increase in A+T-N- for the basal forebrain, postcentral
609 gyrus, middle occipital gyrus, and putamen when comparing to A-T-N-⁷⁷. As described
610 above, large parts of the cingulate gyrus did suggest a monotonic volume decline along
611 ACH group progression. However, ACH did not necessarily reveal the highest evidence
612 in the entire cingulate as there were also portions with highest evidence for non-
613 monotonic volume decline (subcallosal to middle cingulate in AP1 & middle to posterior

614 cingulate in AP2). This renders the cingulate a potential candidate region for brain reserve
615 or biphasic model that requires further research.

616 Under the assumption that patients will convert from negative to positive ATN biomarkers,
617 six patterns of conversions are possible when non-AD pathology ATN groups are
618 additionally included. When testing for monotonic volume decline across these patterns,
619 the highest evidence was found for sequences where Amyloid converts before either Tau
620 or Neurodegeneration (e.g. ATN, ANT), and this was observed in 65% of all gray matter
621 brain areas, especially in AD-related regions. We were able to replicate our finding using
622 ROI-based analyses. In contrast, conversion patterns where Tau converted before
623 Amyloid (TAN, TNA) showed highest evidence for a monotonic volume decline in cortical
624 regions that are atypical for AD pathology. Support for our findings comes from a
625 longitudinal study of 262 non-demented elderly to monitor ATN biomarker progress³². It
626 was found that ACH was the most common path of biomarker conversion, but also ANT,
627 TAN and NAT occurred. In contrast, we observed no evidence for NAT in terms of GM
628 volume decreases. It is worth mentioning that per definition, A-T+ or A-N+ groups are not
629 part of the AD-continuum, these groups might initially point to other diseases like primary
630 tauopathies, hippocampal sclerosis/TDP-43 or ischaemic diseases²⁴. As remarked by ¹
631 and ³², the occurrence of conversion sequences other than ACH in real world data might
632 be explained (a) by coincidence of AD- and non-AD pathologic changes (e.g. in A+T-N+)
633 or (b) long-time subthreshold biomarker trends matching the ACH that are not recognized
634 due to a binary classification with disadvantageous thresholds^{1,32}. Another study provides
635 more support for our hypothesis of an ACH-related temporal order of biomarker progress
636 by monitoring between-group biomarker changes in an longitudinal approach using the
637 ATN classification³¹.

638 Furthermore, our morphometric study revealed evidence to support the consistency
639 between the ACH and Braak staging. Brain regions that are expected to be earlier
640 affected by AD-pathology-linked tau deposition (stage I-IV, MTL, limbic system) showed
641 stronger evidence for monotonic GM volume decline over a sequence of conversions than
642 later stages (stage V/VI, cortical regions). As it is already known that brain atrophy often
643 follows Tau and NFT aggregation⁶⁵, both hypotheses were not mutually exclusive. In our
644 analysis, the stronger evidence for volume decline in the amygdala was surprising when
645 comparing to the hippocampus. As ⁷⁸ remarked, Tau pathology in the amygdala is already
646 beginning with Braak stage I/II. However, this effect was not reproducible with
647 Neurodegeneration by CSF Total Tau.

648 It is known that alternative choices of markers for the N category may have a strong
649 impact on ATN status assignment and longitudinal prediction of cognition^{79,80}. The large
650 pool of possible classification methods limits intercomparability between ATN studies
651 dramatically. In our large study, both variants of ATN classification approaches showed
652 converging evidence for the ACH hypothesis. We were not able to determine a superior
653 combination, as both tested N markers have advantages and caveats. The usage of aHV
654 leads to overall stronger effect sizes but one might argue that there is a circularity in
655 defining ATN groups using volumetry and analyzing ATN-related local brain
656 morphometry. Neurodegeneration defined by aHV is a discrete marker of general
657 neuronal loss and the group assignment was carried out using a ROI-rather than voxel-
658 based approach. GM volume (as analyzed by VBM) on the other hand allows a
659 continuous whole brain local analysis on voxel-level and does not align with N for most
660 brain regions.

661 Although VBM revealed the highest evidence for ACH-related monotonic volume decline
662 in the hippocampus, regions in cortical areas showed compatible monotonic

663 progressions. Taking advantage of the voxel-based approach, differences between
664 sequences could be identified even inside the hippocampus (ACH supports anterior
665 Hippocampus, AP2 posterior hippocampus). It is worth mentioning that the approach is
666 not limited to VBM measurements, in contrast to developmental and plasticity studies
667 stronger expectations for monotonic trajectories do exist for brain volumes in aging and
668 AD. Alternative N categories (such as CSF Total Tau) might also have limitations. The
669 combination of CSF phospho-Tau (T category) and CSF Total Tau (N category) is used
670 in some studies^{26,60,61}, while a strong correlation between both markers strongly
671 underrepresents some ATN groups (A?T+N-, A?T-N+). In a recent publication²⁸ it was
672 possible to replace CSF Total Tau by CSF phospho-Tau without significant impact on the
673 model. Although there is only a weak correlation between aHV and CSF Total Tau as N
674 markers in our study, a similar pattern of local GM volume decline was revealed. This
675 further suggests that a morphometrical analysis with aHV is applicable.

676 **Limitations**

677 This study has several methodological limitations. The first challenge was the
678 hippocampal cut-off estimation: The large sample size does not allow to perform atrophy
679 reference methods like autopsy or visual rating of FDG-PET or MRI. Thus, no estimation
680 of sensitivity or specificity was possible, which prohibits a ROC analysis and Youden's
681 index. Although aHV has a clear unimodal gaussian distribution, it is possible to perform
682 a Gaussian mixture modelling to separate between normal and decreased volumes. A
683 similar approach was performed by⁷⁷. As our data is cross-sectional, no real progression
684 over disease progression and conversions can be modelled and tested. We compensated
685 potential influences of covariates by correcting for demographic marker such as age, sex
686 and education, vascular damage and intracranial volume. This improves comparability
687 (matching) across different ATN groups and increases validity of the underlying cross-

688 sectional progression. Once available, longitudinal DELCODE follow-up data will be used
689 for further validation.

690

691 **Conclusion**

692 Early Amyloid status conversion (before Tau and Neurodegeneration) aligns with pattern
693 of brain volume loss observed during AD progression. The ATN classification and the
694 Amyloid cascade hypothesis are compatible with a monotonic progression of MTL
695 atrophy but using the ATN classification system for staging our study revealed indications
696 for non-monotonic progressions in other areas such as several cortical fields.

697

698

699

700

701

702

703

704

705

706

707

708

709 **Glossary**

ACH	Amyloid Cascade Hypothesis
AD	Alzheimer's disease
DAT	Dementia of Alzheimer's type
aHV	Adjusted hippocampal volume
AN(C)OVA	Analysis of (co-) variance
ATN	Classification based on Amyloid / Tau / Neurodegeneration pathology
BIC	Bayesian Information Criterion
CAT	Computational Anatomy Toolbox
CDR	Clinical Dementia Rating
CERAD	Consortium to establish a registry for Alzheimer's disease
NC	Non-complaining healthy control
CSF	Cerebrospinal fluid
FDR	False Discovery Rate
FLAIR	Fluid attenuated inversion recovery
GM	Gray matter
MCI	Mild Cognitive Impairment
MMSE	Mini-mental state examination
MPRAGE	Magnetization prepared rapid gradient echo

MRI	Magnetic resonance imaging
MTL	Medial temporal lobe
NFT	Neurofibrillary tangles
ROI	Region of interest
SCD	Subjective Cognitive Decline
SPM	Statistical Parametric Mapping
TICV	Total intracranial volume
VBM	Voxel-based Morphometry
WM	White matter
WMH	White matter hyperintensities

710

711

712

713

714

715

716

717

718

719

720 **Declarations**

721 **Ethics approval and consent to participate**

722 DELCODE is retrospectively registered at the German Clinical Trials Register
723 (DRKS00007966), (04/05/2015) and was approved by ethical committees and local
724 review boards. All participants gave written informed consent to participate.

725 **Consent for publication**

726 Not applicable

727 **Availability of Data and Materials**

728 The code used during the current study are available from the corresponding author on
729 reasonable request. Data, study protocol and biomaterials can be shared with partners
730 based on individual data- and biomaterial transfer agreements. Requests can be
731 addressed to the DELCODE steering committee.

732 **Competing Interests**

733 The authors declare that they have no competing interests.

734 **Funding**

735 The study was funded by the German Center for Neurodegenerative Diseases
736 (Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE)), reference number
737 BN012.

738 **Author's contributions**

739 The study was designed by E.D., M.W., A.S. and F.J. Data analysis was performed by
740 N.H. N.H., G.Z., and E.D. wrote the manuscript. All authors reviewed the paper.

741 **Acknowledgements**

742 Not applicable

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757


758

759

760

761 **Supplement**

762 Supplemental File 1: Comparison between selected ATN groups using CSF-total-Tau.



763

764 *Boxplots of age, sex, cognition for selected ATN groups. *: p < .05 after Bonferroni correction, **: p < .001*
765 *after Bonferroni correction. Neurodegeneration (N) by CSF Total Tau.*

766

767

768

769

770

771

772


773

774

775

776 Supplemental File 2: Distribution of ATN status and clinical diagnosis using CSF-total-

777 Tau.



778

779 *Left: percentual distribution of selected ATN groups per clinical diagnosis; right: percentual distribution of*
 780 *clinical diagnosis per ATN groups. Neurodegeneration (N) by CSF Total Tau.*

781

782

783

784

785

786

787

788

789

790 Supplemental File 3: Face validity of ACH using selected ROIs and CSF-total-Tau.

Region	Best sequence	T	P	ACH on rank nr. (of 24)	ACH VX%
AMG	Other2	-7.10	3.17e-12	2	14.42
Hippocampus	ACH	-6.20	7.34e-10	1	47.86
Entorhinal Cortex	Other2	-4.71	1.73e-06	2	43.94
Precuneus	Other3	-2.35	.0095	2	18.00
Braak I/II	ACH	-6.65	5.10e-11	1	50.38
Braak III/IV	Other2	-4.52	4.16e-06	2	16.58
Braak V/VI	Other2	-1.64	.0513	2	5.52

791 *ROI based testing for monotonic volume decline over 24 sequences gained by permutation of the ACH*
792 *sequence. Braak stage volumes are aggregated Freesurfer ROI volumes. Other2: A-T-N- → A+T+N- →*
793 *A+T-N- → A+T+N+; Other3: A+T-N- → A-T-N- → A+T+N- → A+T+N+. ACH VX%: Percentage of voxels*
794 *with highest evidence for ACH sequence inside the ROI mask. Neurodegeneration (N) by CSF Total Tau.*

795

796

797

798

799

800

801


802

803

804

805

806 Supplemental File 4: Face validity of ACH using VBM and CSF-total-Tau.



807

808 *Voxel-based evidence for monotonic volume decline over 24 sequences gained by permutation of the ACH*
809 *sequence (ACH, A-T-N- → A+T-N- → A+T+N- → A+T+N+); AP 1: A+T-N- → A+T+N- → A-T-N- → A+T+N+; AP 2:*
810 *A+T-N- → A-T-N- → A+T+N- → A+T+N+; A: voxels where sequence shows highest evidence; B: percentage*
811 *of gray matter voxels where sequence has highest evidence. Neurodegeneration (N) by CSF Total Tau.*

812

813

814

815

816


817

818

819

820

821 Supplemental File 5: Comparing progression sequences towards AD pathology using
822 VBM and CSF-total-Tau.



823

824 *Voxel-based evidence for monotonic volume decline over 6 possible sequences from A-T-N- towards*
825 *A+T+N+ (ACH, ANT, TAN, TNA, NAT, NTA). Sequences are denoted in the order of biomarker positivity*
826 *along the pathway (e.g. ANT = Amyloid-positivity first, Neurodegeneration second, Tau last). A: voxels*
827 *where sequence shows highest evidence; B: percentage of gray matter voxels where sequence has highest*
828 *evidence. N-first sequences (NAT, NTA) are not shown as only few voxels are supported.*
829 *Neurodegeneration (N) by CSF Total Tau.*

830

831

832

833

834

835 Supplemental File 6: Comparing progression sequences towards AD pathology using
836 selected ROIs and CSF-total-Tau.

Region	Best sequence	T	P	ACH on rank nr. (of 6)	ACH VX%
AMG	TAN	-6.83	1.48e-11	5	49.06
Hippocampus	ACH	-6.13	9.81e-10	1	75.41
Entorhinal Cortex	TAN	-4.67	2.06e-06	2	72.55
Precuneus	ACH	-2.85	.0023	1	54.50
Braak I/II	ACH	-6.53	9.41e-11	1	76.52
Braak III/IV	ACH	-4.34	8.72e-06	1	50.96
Braak V/VI	ACH	-1.60	.0557	1	39.84

837 *ROI based testing for monotonic volume decline over 6 possible sequences from A-T-N- towards A+T+N+*
838 *(ACH, ANT, TAN, TNA, NAT, NTA) including also non-AD continuum groups. Braak stage volumes are*
839 *aggregated Freesurfer ROI volumes. ACH VX%: Percentage of voxels with highest evidence for ACH*
840 *sequence inside the ROI mask. Neurodegeneration (N) by CSF Total Tau.*

841

842

843

844

845

846

847

848

849

850

851

852

853 References

- 854 1. Jack CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease:
855 an updated hypothetical model of dynamic biomarkers. *The Lancet Neurology*. 2013;12(2):207-216.
856 doi:10.1016/S1474-4422(12)70291-0
- 857 2. Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid β deposition, neurodegeneration, and
858 cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. *The Lancet Neurology*.
859 2013;12(4):357-367. doi:10.1016/S1474-4422(13)70044-9
- 860 3. Dean DC, Jerskey BA, Chen K, et al. Brain differences in infants at differential genetic risk for late-
861 onset Alzheimer disease: a cross-sectional imaging study. *JAMA Neurol*. 2014;71(1):11-22.
862 doi:10.1001/jamaneurol.2013.4544
- 863 4. Thal DR, Capetillo-Zarate E, Del Tredici K, Braak H. The development of amyloid beta protein
864 deposits in the aged brain. *Sci Aging Knowledge Environ*. 2006;2006(6):re1.
865 doi:10.1126/sageke.2006.6.re1
- 866 5. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol*.
867 1991;82(4):239-259. doi:10.1007/bf00308809
- 868 6. Janelidze S, Zetterberg H, Mattsson N, et al. CSF A β 42/A β 40 and A β 42/A β 38 ratios: better diagnostic
869 markers of Alzheimer disease. *Ann Clin Transl Neurol*. 2016;3(3):154-165. doi:10.1002/acn3.274
- 870 7. Ritchie C, Smailagic N, Noel-Storr AH, Ukoumunne O, Ladds EC, Martin S. CSF tau and the CSF
871 tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people
872 with mild cognitive impairment (MCI). *Cochrane Database Syst Rev*. 2017;3:CD010803.
873 doi:10.1002/14651858.CD010803.pub2
- 874 8. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. *The Lancet Neurology*.
875 2003;2(10):605-613. doi:10.1016/s1474-4422(03)00530-1
- 876 9. Hampel H, Bürger K, Teipel SJ, Bokde ALW, Zetterberg H, Blennow K. Core candidate neurochemical
877 and imaging biomarkers of Alzheimer's disease. *Alzheimers Dement*. 2008;4(1):38-48.
878 doi:10.1016/j.jalz.2007.08.006
- 879 10. Nathan PJ, Lim YY, Abbott R, et al. Association between CSF biomarkers, hippocampal volume and
880 cognitive function in patients with amnesic mild cognitive impairment (MCI). *Neurobiol Aging*.
881 2017;53:1-10. doi:10.1016/j.neurobiolaging.2017.01.013
- 882 11. Selkoe DJ. The molecular pathology of Alzheimer's disease. *Neuron*. 1991;6(4):487-498.
883 doi:10.1016/0896-6273(91)90052-2
- 884 12. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. *Science*.
885 1992;256(5054):184-185. doi:10.1126/science.1566067
- 886 13. Reitz C. Alzheimer's disease and the amyloid cascade hypothesis: a critical review. *Int J Alzheimers*
887 *Dis*. 2012;2012:369808. doi:10.1155/2012/369808
- 888 14. Hou Y, Dan X, Babbar M, et al. Ageing as a risk factor for neurodegenerative disease. *Nat Rev Neurol*.
889 2019;15(10):565-581. doi:10.1038/s41582-019-0244-7
- 890 15. Yamazaki Y, Zhao N, Caulfield TR, Liu C-C, Bu G. Apolipoprotein E and Alzheimer disease:
891 pathobiology and targeting strategies. *Nat Rev Neurol*. 2019;15(9):501-518. doi:10.1038/s41582-
892 019-0228-7
- 893 16. Prins ND, Scheltens P. White matter hyperintensities, cognitive impairment and dementia: an
894 update. *Nat Rev Neurol*. 2015;11(3):157-165. doi:10.1038/nrneurol.2015.10
- 895 17. Yang J, Pan P, Song W, et al. Voxelwise meta-analysis of gray matter anomalies in Alzheimer's
896 disease and mild cognitive impairment using anatomic likelihood estimation. *J Neurol Sci*.
897 2012;316(1-2):21-29. doi:10.1016/j.jns.2012.02.010

- 898 18. Matsuda H. Voxel-based Morphometry of Brain MRI in Normal Aging and Alzheimer's Disease. *Aging*
899 *and Disease*. 2013;4(1):29-37. Accessed December 2, 2020.
900 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570139/>
- 901 19. A. Armstrong R. A critical analysis of the 'amyloid cascade hypothesis'. *fn*. 2014;3:211-225.
902 doi:10.5114/fn.2014.45562
- 903 20. Busche MA, Hyman BT. Synergy between amyloid- β and tau in Alzheimer's disease. *Nat Neurosci*.
904 2020;23(10):1183-1193. doi:10.1038/s41593-020-0687-6
- 905 21. Schöll M, Lockhart SN, Schonhaut DR, et al. PET Imaging of Tau Deposition in the Aging Human Brain.
906 *Neuron*. 2016;89(5):971-982. doi:10.1016/j.neuron.2016.01.028
- 907 22. Maass A, Landau S, Baker SL, et al. Comparison of multiple tau-PET measures as biomarkers in aging
908 and Alzheimer's disease. *Neuroimage*. 2017;157:448-463. doi:10.1016/j.neuroimage.2017.05.058
- 909 23. Matsuda H. MRI morphometry in Alzheimer's disease. *Ageing Res Rev*. 2016;30:17-24.
910 doi:10.1016/j.arr.2016.01.003
- 911 24. Jack CR, Bennett DA, Blennow K, et al. A/T/N: An unbiased descriptive classification scheme for
912 Alzheimer disease biomarkers. *Neurology*. 2016;87(5):539-547.
913 doi:10.1212/WNL.0000000000002923
- 914 25. Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of
915 Alzheimer's disease. *Alzheimers Dement*. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018
- 916 26. Soldan A, Pettigrew C, Fagan AM, et al. ATN profiles among cognitively normal individuals and
917 longitudinal cognitive outcomes. *Neurology*. 2019;92(14):e1567-e1579.
918 doi:10.1212/WNL.0000000000007248
- 919 27. Altomare D, Wilde A de, Ossenkoppele R, et al. Applying the ATN scheme in a memory clinic
920 population: The ABIDE project. *Neurology*. 2019;93(17):e1635-e1646.
921 doi:10.1212/WNL.0000000000008361
- 922 28. van Maurik IS, Vos SJ, Bos I, et al. Biomarker-based prognosis for people with mild cognitive
923 impairment (ABIDE): a modelling study. *The Lancet Neurology*. 2019;18(11):1034-1044.
924 doi:10.1016/S1474-4422(19)30283-2
- 925 29. Jack CR, Wiste HJ, Therneau TM, et al. Associations of Amyloid, Tau, and Neurodegeneration
926 Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. *JAMA*.
927 2019;321(23):2316-2325. doi:10.1001/jama.2019.7437
- 928 30. Yu J-T, Li J-Q, Suckling J, et al. Frequency and longitudinal clinical outcomes of Alzheimer's AT(N)
929 biomarker profiles: A longitudinal study. *Alzheimers Dement*. 2019;15(9):1208-1217.
930 doi:10.1016/j.jalz.2019.05.006
- 931 31. Guo T, Korman D, Baker SL, Landau SM, Jagust WJ. Longitudinal Cognitive and Biomarker
932 Measurements Support a Unidirectional Pathway in Alzheimer's Disease Pathophysiology. *Biol*
933 *Psychiatry*. 2020. doi:10.1016/j.biopsych.2020.06.029
- 934 32. Tan M-S, Ji X, Li J-Q, et al. Longitudinal trajectories of Alzheimer's ATN biomarkers in elderly persons
935 without dementia. *Alzheimers Res Ther*. 2020;12(1):55. doi:10.1186/s13195-020-00621-6
- 936 33. Ekman U, Ferreira D, Westman E. The A/T/N biomarker scheme and patterns of brain atrophy
937 assessed in mild cognitive impairment. *Sci Rep*. 2018;8(1):8431. doi:10.1038/s41598-018-26151-8
- 938 34. Jessen F, Spottke A, Boecker H, et al. Design and first baseline data of the DZNE multicenter
939 observational study on predementia Alzheimer's disease (DELCODE). *Alzheimers Res Ther*.
940 2018;10(1):15. doi:10.1186/s13195-017-0314-2
- 941 35. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of
942 Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of
943 Health and Human Services Task Force on Alzheimer's Disease. *Neurology*. 1984;34(7):939-944.
944 doi:10.1212/wnl.34.7.939

- 945 36. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: A practical method for grading the state of
946 patients for the clinician. *Journal of Psychiatric Research*. 1975;12(3):189-198. doi:10.1016/0022-
947 3956%2875%2990026-6
- 948 37. Wolfsgruber S, Kleineidam L, Guski J, et al. Minor neuropsychological deficits in patients with
949 subjective cognitive decline. *Neurology*. 2020;95(9):e1134-e1143.
950 doi:10.1212/WNL.00000000000010142
- 951 38. Wellcome Trust Centre for Human Neuroimaging, University College London. Statistical Parametric
952 Mapping software. Accessed February 8, 2022. <https://www.fil.ion.ucl.ac.uk/spm/>
- 953 39. Structural Brain Mapping group, Jena University Hospital. CAT-Toolbox. Accessed February 8, 2022.
954 <http://www.neuro.uni-jena.de/cat/>
- 955 40. Rajapakse JC, Giedd JN, Rapoport JL. Statistical approach to segmentation of single-channel cerebral
956 MR images. *IEEE Trans Med Imaging*. 1997;16(2):176-186. doi:10.1109/42.563663
- 957 41. Ashburner J, Friston KJ. Diffeomorphic registration using geodesic shooting and Gauss-Newton
958 optimisation. *Neuroimage*. 2011;55(3):954-967. doi:10.1016/j.neuroimage.2010.12.049
- 959 42. Laboratory for Computational Neuroimaging, Massachusetts General Hospital. Freesurfer. Accessed
960 February 8, 2022. <http://surfer.nmr.mgh.harvard.edu/>
- 961 43. Fischl B, van der Kouwe A, Destrieux C, et al. Automatically parcellating the human cerebral cortex.
962 *Cereb Cortex*. 2004;14(1):11-22. doi:10.1093/cercor/bhg087
- 963 44. Fischl B, Salat DH, Busa E, et al. Whole Brain Segmentation. *Neuron*. 2002;33(3):341-355.
964 doi:10.1016/s0896-6273(02)00569-x
- 965 45. Busatto GF, Diniz BS, Zanetti MV. Voxel-based morphometry in Alzheimer's disease. *Expert Rev*
966 *Neurother*. 2008;8(11):1691-1702. doi:10.1586/14737175.8.11.1691
- 967 46. Ferreira LK, Diniz BS, Forlenza OV, Busatto GF, Zanetti MV. Neurostructural predictors of Alzheimer's
968 disease: a meta-analysis of VBM studies. *Neurobiol Aging*. 2011;32(10):1733-1741.
969 doi:10.1016/j.neurobiolaging.2009.11.008
- 970 47. Leandrou S, Petroudi S, Kyriacou PA, Reyes-Aldasoro CC, Pattichis CS. Quantitative MRI Brain Studies
971 in Mild Cognitive Impairment and Alzheimer's Disease: A Methodological Review. *IEEE Rev Biomed*
972 *Eng*. 2018;11:97-111. doi:10.1109/RBME.2018.2796598
- 973 48. Teipel SJ, Meindl T, Grinberg L, Heinsen H, Hampel H. Novel MRI techniques in the assessment of
974 dementia. *Eur J Nucl Med Mol Imaging*. 2008;35 Suppl 1:S58-69. doi:10.1007/s00259-007-0703-z
- 975 49. Baker SL, Maass A, Jagust WJ. Considerations and code for partial volume correcting 18F-AV-1451
976 tau PET data. *Data Brief*. 2017;(15):648-657. doi:10.1016/j.dib.2017.10.024
- 977 50. Iglesias JE, Augustinack JC, Nguyen K, et al. A computational atlas of the hippocampal formation
978 using ex vivo, ultra-high resolution MRI: Application to adaptive segmentation of in vivo MRI.
979 *Neuroimage*. 2015;115:117-137. doi:10.1016/j.neuroimage.2015.04.042
- 980 51. Koncz R, Sachdev PS. Are the brain's vascular and Alzheimer pathologies additive or interactive? *Curr*
981 *Opin Psychiatry*. 2018;31(2):147-152. doi:10.1097/YCO.0000000000000395
- 982 52. Roseborough A, Ramirez J, Black SE, Edwards JD. Associations between amyloid β and white matter
983 hyperintensities: A systematic review. *Alzheimers Dement*. 2017;13(10):1154-1167.
984 doi:10.1016/j.jalz.2017.01.026
- 985 53. Toledo JB, Arnold SE, Raible K, et al. Contribution of cerebrovascular disease in autopsy confirmed
986 neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. *Brain*.
987 2013;136(Pt 9):2697-2706. doi:10.1093/brain/awt188
- 988 54. Mortamais M, Artero S, Ritchie K. Cerebral white matter hyperintensities in the prediction of
989 cognitive decline and incident dementia. *Int Rev Psychiatry*. 2013;25(6):686-698.
990 doi:10.3109/09540261.2013.838151
- 991 55. Schmidt P. *Bayesian Inference for Structured Additive Regression Models for Large-Scale Problems*
992 *with Applications Tomedical Imaging: Dissertation an Der Fakultät Für Mathematik, Informatik Und*

- 993 *Statistik Der Ludwig-Maximilians-Universität München*. [Dissertation]: Ludwig-Maximilians-
994 Universität München; 2017. <http://nbn-resolving.de/urn:nbn:de:bvb:19-203731>
- 995 56. Schmidt P. LST. A lesion segmentation tool for SPM. Accessed March 7, 2022. <http://www.statistical->
996 [modelling.de/lst.html](http://www.statistical-modelling.de/lst.html)
- 997 57. Bertens D, Tijms BM, Scheltens P, Teunissen CE, Visser PJ. Unbiased estimates of cerebrospinal fluid
998 β -amyloid 1-42 cutoffs in a large memory clinic population. *Alzheimers Res Ther*. 2017;9(1):8.
999 doi:10.1186/s13195-016-0233-7
- 1000 58. Schwarz G. Estimating the Dimension of a Model. *Ann Statist*. 1978;6(2).
1001 doi:10.1214/aos/1176344136
- 1002 59. Hwang J, Jeong JH, Yoon SJ, et al. Clinical and Biomarker Characteristics According to Clinical
1003 Spectrum of Alzheimer's Disease (AD) in the Validation Cohort of Korean Brain Aging Study for the
1004 Early Diagnosis and Prediction of AD. *J Clin Med*. 2019;8(3). doi:10.3390/jcm8030341
- 1005 60. Burnham SC, Coloma PM, Li Q-X, et al. Application of the NIA-AA Research Framework: Towards a
1006 Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study. *J*
1007 *Prev Alzheimers Dis*. 2019;6(4):248-255. doi:10.14283/jpad.2019.25
- 1008 61. Grøntvedt GR, Lauridsen C, Berge G, et al. The Amyloid, Tau, and Neurodegeneration (A/T/N)
1009 Classification Applied to a Clinical Research Cohort with Long-Term Follow-Up. *J Alzheimers Dis*.
1010 2020;74(3):829-837. doi:10.3233/JAD-191227
- 1011 62. Kakeda S, Korogi Y. The efficacy of a voxel-based morphometry on the analysis of imaging in
1012 schizophrenia, temporal lobe epilepsy, and Alzheimer's disease/mild cognitive impairment: a review.
1013 *Neuroradiology*. 2010;52(8):711-721. doi:10.1007/s00234-010-0717-2
- 1014 63. Karas GB, Scheltens P, Rombouts SARB, et al. Global and local gray matter loss in mild cognitive
1015 impairment and Alzheimer's disease. *Neuroimage*. 2004;23(2):708-716.
1016 doi:10.1016/j.neuroimage.2004.07.006
- 1017 64. Chételat G, Landeau B, Eustache F, et al. Using voxel-based morphometry to map the structural
1018 changes associated with rapid conversion in MCI: a longitudinal MRI study. *Neuroimage*.
1019 2005;27(4):934-946. doi:10.1016/j.neuroimage.2005.05.015
- 1020 65. Pini L, Pievani M, Bocchetta M, et al. Brain atrophy in Alzheimer's Disease and aging. *Ageing Res Rev*.
1021 2016;30:25-48. doi:10.1016/j.arr.2016.01.002
- 1022 66. Baron JC, Chételat G, Desgranges B, et al. In vivo mapping of gray matter loss with voxel-based
1023 morphometry in mild Alzheimer's disease. *Neuroimage*. 2001;14(2):298-309.
1024 doi:10.1006/nimg.2001.0848
- 1025 67. Ramos Bernardes da Silva Filho S, Oliveira Barbosa JH, Rondinoni C, et al. Neuro-degeneration profile
1026 of Alzheimer's patients: A brain morphometry study. *Neuroimage Clin*. 2017;15:15-24.
1027 doi:10.1016/j.nicl.2017.04.001
- 1028 68. Zanchi D, Giannakopoulos P, Borgwardt S, Rodriguez C, Haller S. Hippocampal and Amygdala Gray
1029 Matter Loss in Elderly Controls with Subtle Cognitive Decline. *Front Aging Neurosci*. 2017;9:50.
1030 doi:10.3389/fnagi.2017.00050
- 1031 69. Jones BF, Barnes J, Uylings HBM, et al. Differential regional atrophy of the cingulate gyrus in
1032 Alzheimer disease: a volumetric MRI study. *Cereb Cortex*. 2006;16(12):1701-1708.
1033 doi:10.1093/cercor/bhj105
- 1034 70. Kumar D, Ganeshpurkar A, Kumar D, Modi G, Gupta SK, Singh SK. Secretase inhibitors for the
1035 treatment of Alzheimer's disease: Long road ahead. *Eur J Med Chem*. 2018;148:436-452.
1036 doi:10.1016/j.ejmech.2018.02.035
- 1037 71. van Dyck CH. Anti-Amyloid- β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise.
1038 *Biol Psychiatry*. 2018;83(4):311-319. doi:10.1016/j.biopsych.2017.08.010

- 1039 72. Masliah E, Mallory M, Hansen L, Richard D, Alford M, Terry R. Synaptic and neuritic alterations
1040 during the progression of Alzheimer's disease. *Neuroscience Letters*. 1994;174(1):67-72.
1041 doi:10.1016/0304-3940(94)90121-X
- 1042 73. Knowles RB, Gomez-Isla T, Hyman BT. Abeta associated neuropil changes: correlation with neuronal
1043 loss and dementia. *J Neuropathol Exp Neurol*. 1998;57(12):1122-1130. doi:10.1097/00005072-
1044 199812000-00003
- 1045 74. Fortea J, Vilaplana E, Alcolea D, et al. Cerebrospinal fluid β -amyloid and phospho-tau biomarker
1046 interactions affecting brain structure in preclinical Alzheimer disease. *Ann Neurol*. 2014;76(2):223-
1047 230. doi:10.1002/ana.24186
- 1048 75. Montal V, Vilaplana E, Alcolea D, et al. Cortical microstructural changes along the Alzheimer's
1049 disease continuum. *Alzheimer's & Dementia*. 2018;14(3):340-351. doi:10.1016/j.jalz.2017.09.013
- 1050 76. Stern Y, Arenaza-Urquijo EM, Bartrés-Faz D, et al. Whitepaper: Defining and investigating cognitive
1051 reserve, brain reserve, and brain maintenance. *Alzheimer's & Dementia*. 2020;16(9):1305-1311.
1052 doi:10.1016/j.jalz.2018.07.219
- 1053 77. Ingala S, Boer C de, Masselink LA, et al. Application of the ATN classification scheme in a population
1054 without dementia: Findings from the EPAD cohort. *Alzheimer's & Dementia*. 2021;17(7):1189-1204.
1055 doi:10.1002/alz.12292
- 1056 78. Nelson PT, Abner EL, Patel E, et al. The Amygdala as a Locus of Pathologic Misfolding in
1057 Neurodegenerative Diseases. *J Neuropathol Exp Neurol*. 2018;77(1):2-20. doi:10.1093/jnen/nlx099
- 1058 79. Mattsson-Carlgen N, Leuzy A, Janelidze S, et al. The implications of different approaches to define
1059 AT(N) in Alzheimer disease. *Neurology*. 2020;94(21):e2233-e2244.
1060 doi:10.1212/WNL.00000000000009485
- 1061 80. Illán-Gala I, Pegueroles J, Montal V, et al. Challenges associated with biomarker-based classification
1062 systems for Alzheimer's disease. *Alzheimers Dement (Amst)*. 2018;10:346-357.
1063 doi:10.1016/j.dadm.2018.03.004
1064